Literature DB >> 23132206

Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States.

B Ashleigh Guadagnolo1, Jinhai Huo, Kai-Ping Liao, Thomas A Buchholz, Prajnan Das.   

Abstract

BACKGROUND: Our goal was to investigate utilization trends for advanced radiation therapy (RT) technologies, such as intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery (SRS), in the last year of life among patients diagnosed with metastatic cancer.
METHODS: We used the Surveillance, Epidemiology and End Results (SEER)-Medicare linked databases to analyze claims data in the last 12 months of life for 64,525 patients diagnosed with metastatic breast, colorectal, lung, pancreas, and prostate cancers from 2000 to 2007. Logistic regression modeling was conducted to analyze potential demographic, health services, and treatment-related variables' influences on receipt of advanced RT.
RESULTS: Among the 19,161 (29.7%) patients who received radiation therapy, there was a significant decrease in the proportion of patients who received the simplest radiation technique (ie, 2D-radiation therapy) (P < .0001), and significant increases in the proportions of patients receiving more advanced radiation techniques (ie, IMRT, and SRS; P < .0001 for all curves); although the rates for use of IMRT and SRS in 2007 remained under 5%. On multivariate analyses, receipt of RT varied significantly by non-clinical characteristics such as race, marital status, neighborhood income, and SEER region. Patients who received hospice care in the last year of life were more likely to receive radiation therapy (OR = 1.35, 95% CI = 1.30-1.40) but less likely to be treated with IMRT (OR = 0.76, 95% CI = 0.62-0.92).
CONCLUSIONS: Although the proportion of patients receiving RT in the last year of life for metastatic cancer did not change for most of the past decade, we observed significant trends toward more advanced radiation techniques.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 23132206      PMCID: PMC3688625          DOI: 10.1002/cncr.27835

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  The sources of the SGR "hole".

Authors:  Ali Alhassani; Amitabh Chandra; Michael E Chernew
Journal:  N Engl J Med       Date:  2011-12-21       Impact factor: 91.245

Review 2.  Stereotactic body radiation for the spine: a review.

Authors:  Sheema Chawla; Michael C Schell; Michael T Milano
Journal:  Am J Clin Oncol       Date:  2013-12       Impact factor: 2.339

3.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

4.  Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients.

Authors:  Carrie N Klabunde; Linda C Harlan; Joan L Warren
Journal:  Med Care       Date:  2006-10       Impact factor: 2.983

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

7.  Potential for cancer related health services research using a linked Medicare-tumor registry database.

Authors:  A L Potosky; G F Riley; J D Lubitz; R M Mentnech; L G Kessler
Journal:  Med Care       Date:  1993-08       Impact factor: 2.983

8.  A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.

Authors:  Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag
Journal:  Ann Epidemiol       Date:  2007-05-25       Impact factor: 3.797

9.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

10.  The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms.

Authors:  Max Dahele; Suresh Senan
Journal:  Cancer Res Treat       Date:  2011-06-30       Impact factor: 4.679

View more
  12 in total

1.  Palliative radiotherapy for thoracic spine metastases: Dosimetric advantage of three-dimensional conformal plans.

Authors:  Seung-Gu Yeo
Journal:  Oncol Lett       Date:  2015-05-13       Impact factor: 2.967

2.  Increasing use of advanced radiation therapy technologies in the last 30 days of life among patients dying as a result of cancer in the United States.

Authors:  B Ashleigh Guadagnolo; Kai-Ping Liao; Sharon H Giordano; Linda S Elting; Thomas A Buchholz; Ya-Chen Tina Shih
Journal:  J Oncol Pract       Date:  2014-04-22       Impact factor: 3.840

3.  Does dissemination of guidelines alone increase the use of palliative single-fraction radiotherapy? Initial report of a longitudinal change management campaign at a provincial cancer program.

Authors:  J O Kim; N Hanumanthappa; Y T Chung; J Beck; R Koul; B Bashir; A Cooke; A Dubey; J Butler; M Nashed; W Hunter; A Ong
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

4.  Advanced imaging and hospice use in end-of-life cancer care.

Authors:  Michaela A Dinan; Lesley H Curtis; Soko Setoguchi; Winson Y Cheung
Journal:  Support Care Cancer       Date:  2018-05-04       Impact factor: 3.603

5.  Costs of care for lung and colon cancer patients receiving chemotherapy following FDA policy changes.

Authors:  Kevin T Stroupe; Elizabeth Tarlov; Thomas W Weichle; Qiuying L Zhang; Laura C Michaelis; Howard Ozer; Ramon Durazo-Arvizu; Denise M Hynes
Journal:  Support Care Cancer       Date:  2014-06-10       Impact factor: 3.603

6.  Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer.

Authors:  Timothy J Robinson; Michaela A Dinan; Yanhong Li; W Robert Lee; Shelby D Reed
Journal:  J Palliat Med       Date:  2015-08-04       Impact factor: 2.947

7.  Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer.

Authors:  Nirav S Kapadia; Luca F Valle; Julie A George; Reshma Jagsi; Thomas A D'Amico; Elisabeth U Dexter; Fawn D Vigneau; Feng Ming Kong
Journal:  Ann Thorac Surg       Date:  2017-10-26       Impact factor: 4.330

Review 8.  Considerations for observational research using large data sets in radiation oncology.

Authors:  Reshma Jagsi; Justin E Bekelman; Aileen Chen; Ronald C Chen; Karen Hoffman; Ya-Chen Tina Shih; Benjamin D Smith; James B Yu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-09-01       Impact factor: 7.038

Review 9.  Radiation treatment in older patients: a framework for clinical decision making.

Authors:  Grace L Smith; Benjamin D Smith
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

10.  Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer.

Authors:  Sun Hyun Bae; Seong Kwon Moon; Yong Ho Kim; Kwang Hwan Cho; Eung Jin Shin; Moon Sung Lee; Chang Beom Ryu; Bong Min Ko; Jina Yun
Journal:  Radiat Oncol J       Date:  2015-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.